This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters to the Editor

A Crossover Study of Prolactin Changes Associated With Risperidone and Olanzapine

Cher-Yeang Lin, MD; Po-Lun Wu, MD; Carmine M. Pariante, MD, PhD; and Kuan-Pin Su, MD

Published: September 15, 2006

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: We read with interest the recent article by Melkersson1 that described the differential effect on prolactin elevation in schizophrenic patients treated with clozapine (none of the patients had elevated prolactin), olanzapine (24% of the patients had elevated prolactin), and risperidone (89% of the patients had elevated prolactin). Previous head-to-head clinical trials have revealed similar results.2-5 However, these comparison studies might be limited by the individual variation in endocrine profiles, demographic variables such as age and gender, and concomitant medication use.6,7‘ ‹


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 67

Quick Links: Dementia , Neurologic and Neurocognitive

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...